PUBLIC COMPANY
save$REGNREGENERON PHARMACEUTICALS, INC.
$REGN812.08+1.77%Tarrytown, NY, USupdated 4h ago
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
community read0 votes
pipeline
30
marketed
8
phase 3
9
catalysts ytd
8
approvals ytd
3
recalls ytd
0
Pipeline(30)
view full pipeline →pipeline depth30 products
1Preclinical1Phase 14Phase 29Phase 38Marketed4Unknown3pre_registration
Marketed
(atoltivimab + maftivimab + odesivimab)
Ebolavirus Infections (Ebola Hemorrhagic Fever)
MarketedEYLEA HD
wet AMD, diabetic macular edema, retinal vein occlusion
Placenta growth factorVascular endothelial growth factor A, long form
MarketedEylea
Diabetic Macular Edema
Marketedcemiplimab
Melanoma
Programmed cell death protein 1
Marketeddupilumab
Chronic Urticaria
Interleukin-4 receptor subunit alpha
Marketedevinacumab
Homozygous Familial Hypercholesterolemia (HoFH)
Marketedlinvoseltamab
Refractory Multiple Myeloma
Marketedsodium thiosulfate
Hearing Disorders
Phase 3(atisnolerbart + bremzalerbart + umesolerbart)
Birch Pollen Allergy
Phase 3cemdisiran + pozelimab
Myasthenia Gravis
Phase 3fianlimab
Metastatic Melanoma
Lymphocyte activation gene 3 protein
Phase 3freneslerbart + mevonlerbart
Cat Allergy
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase1Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
- phase3A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- —A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- —An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
- phase2A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
- phase3Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- phase4Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
- phase3Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 1, 26SELLRYAN ARTHUR F· −$31K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$11K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$10K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$7K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$6K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$6K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$3K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$2K↗
- Apr 1, 26SELLRYAN ARTHUR F· −$771↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$16K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$16K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$9K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$8K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$7K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$6K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$5K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$4K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$2K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$2K↗
- Mar 2, 26SELLRYAN ARTHUR F· director−$2K↗
🐶 Hiring Signal
next earnings Oct 28, 2026
Where REGENERON PHARMACEUTICALS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- 7 companies hiring in North Carolina nowLooking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.biospace · 1d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 7d ago
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 14d ago
- 7 companies hiring in New York nowLooking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.biospace · 15d ago
- 6 companies hiring in Cambridge nowLooking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.biospace · 22d ago
- FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug ManufacturingFDA announces the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American global competitiveness, strengthen domestic drug manufac…fda_press · 1mo ago
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.biopharma_dive · 2mo ago
- Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive · 3mo ago
- STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and morePresident Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White Housestat · 3mo ago
- FDA approves Regeneron’s hearing loss gene therapyOtarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…biopharma_dive · 3mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that